







IMDRF Status Update

Dr. Andrzej Rys

IMDRF Chair 2023

Directorate-General for Health and Food Safety (DG SANTE)

European Commission

16 February 2023 – 26th GHWP Annual Meeting





Governance



The International Medical Device Regulators Forum (IMDRF)

Mission: Accelerate international medical device regulatory convergence - whereby the requirements and approaches become more similar or aligned as a result of the adoption of the same technical documents, standards and scientific principles and similar regulatory practices and procedures.

Result: the EU MDR/IVDR take onboard a substantial amount of IMDRF/GHTF principles

















Official Observers:





Affiliate Members: Regional Harmonisation Initiatives (GHWP, ARF, APEC, PAHO)

New membership: Affiliate Members




Working Groups

Adverse Event Terminology



Cybersecurity



Good Regulatory Review Practice



Personalised Medical Devices



Quality Management Systems



Regulated Product Submission



Software as a Medical Device



New group = Good Machine Learning Practices







IMDRF Strategic plan 2021-2025

IMDRF status update at the 26th GHWP Annual Meeting – 16 February 2023

- **1. Managing** regulatory **challenges** for medical devices and innovative technologies by providing **timely and appropriate** guidance
- 2. Strengthening post-market surveillance for medical devices and implement regulatory life cycle processes



Our objectives

Key priorities

Pre-market

Develop a risk calibrated regulatory approach for innovations and promote harmonized pre-market review requirements for medical devices

Post-market

Leverage post-market monitoring and surveillance to ensure accessibility to safe and effective innovations for patients

Relationship building

IMDRF will seek opportunities to develop stronger relationships with organizations that help international medical device regulatory convergence



Key priorities – status February 2023

1. Pre-market

- Artificial Intelligence enabled Medical Device: 1 guidance finalised (published)
- Good Regulatory Review Practices (GRRP): 2 guidance finalised (1 published, 1 under publication)
- Personalised Medical Devices (PMD): 2
 guidance with an estimated finalisation in
 Q2 2023
- Regulated Product Submissions (RPS): public consultation (being launched)
- SaMD: public consultation estimated in Q2 2023

2. Post-market

- Cybersecurity: 2 new guidance with an estimated finalisation in Q2 2023
- Adverse Event Terminology (AET): review in 2021, 2022 and most recently in Jan 2023 (currently under publication)
- Quality Management System (QMS): new group



Key priorities – status February 2023

Relationship with actors

- Improved IMDRF operational transparency, tracking and accountability practices.
- Regional harmonization initiatives delegates invited to the IMDRF MC Open Session.
- New Affiliate membership!



New membership: Affiliate member

Regulatory Authorities who:

- ✓ would like to engage with IMDRF (who are not Official Observers),
- are using IMDRF documents in part or in whole as the basis for their own regulatory framework.

Are invited to:

- ✓ participate in IMDRF by attending "open" meetings,
- ✓ participate in open Working Groups,
- ✓ provide input to open consultations.



Areas for further work

- ✓ Ensuring timely availability of necessary guidance whilst facilitating open and transparent public consultations,
- Development of trainings with interested partners to ensure appropriate dissemination to all actors,
- ✓ Technical capacity building and regulatory knowledge transfer.













SAVE THE DATE!

BRUSSELS, BELGIUM 27-31 MARCH 2023

BERLIN, GERMANY
25-29 SEPTEMBER 2023

Register at www.imdrf2023.com











SAVE THE DATE!



BRUSSELS, BELGIUM 27-28 MARCH 2023





Joint IMDRF / Industry Workshop — 27 March 2023

Theme: The life cycle of medical devices: the importance of post-market-related activities

Session 1: Safety notices and vigilance

Regulators, industry and healthcare professional perspectives.

Session 2: Real World Evidence

Gathering and uses of RWE.

Sessions 3, 4 and 5: Post-market considerations for software including AI: opportunities and challenges

- How to distinguish between safety signals and noise,
- Changes requiring post-market validation,
- Monitoring of endpoints, bias, change management.



IMDRF Stakeholder Forum – 28 March 2023

Session 1: Opening remarks and welcome

Session 2: Regulatory updates from IMDRF Management Committee and Official Observers

- Australia, Brazil, Canada, China, EU, Japan, Singapore, South Korea, United Kingdom, United States of America.
- Argentina and WHO

Session 3: Progress overview of IMDRF work items

 Adverse Event Terminology (USA/EU), Good Regulatory Review Practices (USA), Cybersecurity (USA/Canada), Personalized Medical Devices (Australia), Quality Management Systems (USA/EU), Regulated Product Submission (Canada/USA), Software as a Medical Device (USA/Canada).

Sessions 4: Stakeholder session

 African Medical Device Forum, Global Harmonization Working Party, Pan American Health Organization, the Global Diagnostic Imaging, Healthcare ICT and Radiation Therapy Trade Association (DITTA) and the Global Medical Technology Alliance (GMTA).





THANK YOU / QUESTIONS

IMDRF 2023 Secretariat

IMDRF2023@ec.europa.eu

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.





